Increased Bone Marrow Plasma-Cell Percentage Predicts Outcomes in Newly Diagnosed Multiple Myeloma Patients

Abstract Background and aim: A cure for the heterogeneous hematological malignancy Multiple Myeloma (MM) is yet to be developed. To date, the early risk factors associated with poor outcomes in MM have not been fully elucidated. Studies have shown an aberrant complement system in MM patients, but the precise association necessitates elucidation. Therefore, this study scrutinizes the correlation between serum complement level and the disease outcome of MM patients.Materials and methods: A retrospective analysis of 72 MM patients (new diagnosis) with complement C4 and C3 along with common laboratory indicators was done. The Pearson’s χ2 test and the Mann–Whitney U test were done to evaluate categorical or binary variables and inter-group variance, respectively. Kaplan-Meier test and Cox’s proportional hazards regression were employed for quantitation of overall survival (OS) and univariate or multivariate analyses, respectively.Results: The Cox proportional hazard model analysis unveiled the following: platelet≤115.5×10^9/L(HR=5.82，95%CI=2.522-13.436, P<0.001)， complement C4≤0.095g/L(HR=3.642, 95%CI=1.486-8.924,P=0.005), age≥67 years(HR=0.191, 95%CI=0.078-0.47, P<0.001)，bone marrow plasma cell percentage≥30.75% (HR=0.171, 95%CI=0.06-0.482, P=0.001) can be employed as independent predictors of OS. Of these, advanced age, low platelet level, and a high proportion of bone marrow plasma cells have been implicated in poor outcomes in MM patients. Interestingly, a low complement 4 level can function as a new indicator of poor prognosis in MM patients.Conclusion: Low levels of C4 are indicative of a poor outcome in newly diagnosed MM patients.

Download Full-text

Analysis of CD138+ Plasma Cell Percentage in Bone Marrow Section Using Image Analyzer: Discrepancies of Bone Marrow Plasma Cell Count between Aspiration and Biopsy Section in Multiple Myeloma

Clinical Lymphoma Myeloma & Leukemia ◽

10.1016/j.clml.2015.07.260 ◽

2015 ◽

Vol 15 ◽

pp. e96 ◽

Cited By ~ 2

Author(s):

N. Lee ◽

S.Y. Moon ◽

S.Y. Kim ◽

S.M. Hwang ◽

H.K. Park ◽

...

Keyword(s):

Multiple Myeloma ◽

Bone Marrow ◽

Cell Count ◽

Plasma Cell ◽

Image Analyzer ◽

Cell Percentage ◽

Bone Marrow Plasma

Download Full-text

Hematopoietic Score for the Prognostic Evaluation of Multiple Myeloma Patients Undergoing First-Line Treatment With A Bortezomib-Based Regimen

10.21203/rs.3.rs-137751/v1 ◽

2021 ◽

Author(s):

JingSong He ◽

XiaoYan Yue ◽

XiaoYan Han ◽

DongHua He ◽

Yi Zhao ◽

...

Keyword(s):

Multiple Myeloma ◽

Bone Marrow ◽

Plasma Cell ◽

Multivariable Analysis ◽

Line Treatment ◽

First Line ◽

Prognostic Predictors ◽

Cell Percentage ◽

Bone Marrow Plasma ◽

First Line Treatment

Abstract Background: It is very important to evaluate the prognosis of multiple myeloma (MM) patients before starting treatment. Although hematopoietic status may have a significant impact on patient survival, it has not received sufficient attention in current clinical practice. Methods: This was a retrospective study of 328 newly diagnosed MM patients received first-line treatment with a bortezomib-based regimen. The effects of hematopoietic factors, including hemoglobin (Hgb) levels, mean corpuscular volume (MCV), and platelet count (Plt) on the prognosis of the patients were analysed. Results: Hgb<100 g/L, MCV>99.1fL and Plt<150×109/L significantly affect the progression-free survival (PFS) and overall survival (OS) of MM patients, each of the above factors was assigned a value of 1 to generate a hematopoietic score. According to the results, 93 (28.4%), 103 (31.4%), 90 (27.4%) and 42 (12.8%) patients had a score of 0, 1, 2, 3, respectively. The median PFS were 38.7, 55.9, 23.9 and 16.7 months, respectively (P<0.001), and the median OS were not reached (NR), 68.4months, 53.6 and 33.2 months, respectively (P<0.001). Multivariable analysis showed that hematopoietic score (2-3 vs 0-1, HR, 1.64) and bone marrow plasma cell percentage (>30%, HR, 1.54) are independent prognostic predictors for PFS; age (≥70 years, HR, 1.67), hematopoietic score (2-3 vs 0-1, HR, 1.60), serum creatinine level (>177umol/L, HR, 2.15) and bone marrow plasma cell percentage (>30%, HR, 1.81) are independent prognostic predictors of OS. Conclusions: This study suggests that the hematopoietic score can be used to evaluate the prognosis of newly treated MM patients in the era of new drugs. However, there is still a need to enlarge the number of cases and carry out prospective research to validate this conclusion.

Download Full-text

Multiple myeloma: circulating lymphocytes that express plasma cell antigens

Blood ◽

10.1182/blood.v64.2.352.bloodjournal642352 ◽

1984 ◽

Vol 64 (2) ◽

pp. 352-356

Author(s):

GJ Ruiz-Arguelles ◽

JA Katzmann ◽

PR Greipp ◽

NJ Gonchoroff ◽

JP Garton ◽

...

Keyword(s):

Multiple Myeloma ◽

Bone Marrow ◽

Plasma Cell ◽

Peripheral Blood ◽

Plasma Cells ◽

Peripheral Blood Lymphocytes ◽

Tumor Burden ◽

B Cell Differentiation ◽

Blood Lymphocytes ◽

Bone Marrow Plasma

The bone marrow and peripheral blood of 14 patients with multiple myeloma were studied with murine monoclonal antibodies that identify antigens on plasma cells (R1–3 and OKT10). Peripheral blood lymphocytes expressing plasma cell antigens were found in six cases. Five of these cases expressed the same antigens that were present on the plasma cells in the bone marrow. Patients that showed such peripheral blood involvement were found to have a larger tumor burden and higher bone marrow plasma cell proliferative activity. In some patients, antigens normally found at earlier stages of B cell differentiation (B1, B2, and J5) were expressed by peripheral blood lymphocytes and/or bone marrow plasma cells.

Download Full-text